AMAG Pharmaceuticals announced that it has updated the labeling for Feraheme (ferumoxytol injection) to include additional post-marketing safety data.
Your search for evid returned 2822 results
There is minimal toxicity associated with the use of thalidomide in malignant pleural mesothelioma; however, there is also no evidence of benefit in progression free survival or overall survival, according to researchers at the American Society of Clinical Oncology’s 2011 Annual Meeting.
Data from an international, multicenter, open-label, Phase 2 clinical study suggested that crizotinib was safe and well-tolerated with preliminary evidence of improved symptoms and clinically meaningful antitumor activity in patients with pretreated ALK-rearranged metastatic non-small cell lung cancer, investigators reported during the American Society of Clinical Oncology’s 2011 Annual Meeting.
In a Phase 3, multicenter trial involving patients ≥65 years who were newly diagnosed with de novo or secondary acute myeloid leukemia, decitabine demonstrated an overall survival advantage over standard therapies, according to data presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.
The combination of amonafide + cytarabine does not provide a complete response benefit over treatment with daunorubicin + cytarabine in patients with secondary acute myeloid leukemia, according to a presentation at the American Society of Clinical Oncology’s 2011 Annual Meeting.
Initial analysis of the effects of duloxetine vs. placebo in patients with chronic low back pain indicates duloxetine has both brain and behavioral effects in this population, Kevin A. Johnson, of Stanford University School of Medicine, Palo Alto, CA, and colleagues reported during the American Pain Society’s 30th Annual Scientific Meeting.
A multicenter pediatric pain clinical trials consortium will facilitate better study design and ensure children experience no additional burden for participation in research, including enduring even slightly undertreated pain, a panel of pediatric pain experts said during the American Pain Society’s 30th Annual Scientific Meeting.
Maximizing acute pain relief while minimizing the incidence of adverse events prevents the evolution of acute postoperative pain into chronic pain.
InterMune announced positive data from its CAPACITY Program studying pirfenidone for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).
Amarin Corporation announced positive results from its Phase 3 study of AMR101 for the treatment of patients with high triglycerides (TG) without increasing LDL-C levels in patients on background statin therapy.